Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis
2020 · Nature Communications · 44 citations
https://doi.org/10.1038/s41467-020-15615-z
M
Matthew J. Martin
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
94
Papers
2.7K
Citations
24
h-index
34
i10-index
Matthew J. Martin is an academic researcher from Stony Brook University Hospital. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & PI3K/AKT/mTOR signaling in cancer & HER2/EGFR in Cancer Research. The author has an h-index of 24, co-authored 80 publications.
Papers by this author
worksThe landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells
2022 · npj Precision Oncology · 36 citations
https://doi.org/10.1038/s41698-022-00337-w
Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer
2024 · Communications Biology · 26 citations
https://doi.org/10.1038/s42003-024-06190-w
Phosphoproteomics of osimertinib-tolerant persister cells reveals targetable kinase-substrate signatures
2025 · Molecular Systems Biology · 2 citations
https://doi.org/10.1038/s44320-025-00141-1
Figure S3 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27013640.v1
Figure S4 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27013637.v1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat